A group of execs who helped steer Durata and its antibiotic Dalvance to a $675 million buyout by Actavis (now Allergan) have landed a $40 million Series A to launch a new biotech called Iterum Therapeutics.
Researchers at South Korea's Institute for Basic Science are developing a drug-delivering glucose monitoring microneedle patch made of gold-doped graphene. It showed promise on diabetic mice, according to a just-published paper in Nature Nanotechnology.
AstraZeneca's high hopes for its heart drug Brilinta took a major hit on Wednesday. According to new top-line data from the much-anticipated SOCRATES trial, the clot-fighting med failed to beat aspirin at treating stroke patients, missing its primary goal of delaying stroke, heart attack and cardiovascular death.
Janssen has signed up two more therapy areas to its unique Disease Interception Accelerator (DIA) program as it continues to look for future growth and deals from new places.
The U.K.'s National Health Service doesn't have the reputation of being particularly technology savvy. In fact, it's had a long and public struggle--that's not yet complete--to get electronic medical records into place.
Months after its formation last fall, CSL's flu vaccines unit Seqirus is a loss-making entity. However, leadership there believes the operation can achieve "industry leadership" in 5 to 10 years by relying on a move into quadrivalent vaccines, the launch of Fluad and emerging markets growth.
The World Health Organization has warned that the Zika R&D; frenzy may not culminate in a vaccine in time for the current outbreak, but Sanofi Chief Scientific Officer Gary Nabel won't take that for an answer. Nabel says it can be done, but it means turning the traditional vaccine development model on its head.
AstraZeneca's hopes of beefing up its heart drug Brilinta with a new indication took a major hit today after it released data showing the pill did not help stroke patients any better than a drug first discovered in the 19th century.
Johnson & Johnson's Janssen arm is dialing up research through its Disease Interception Accelerator (DIA), a unit focused on predicting and preventing certain diseases through new diagnostic and therapeutic approaches. The company is kicking off two new projects for COPD and gestational diabetes aimed at uncovering the biological underpinnings of the diseases.
There aren't a lot of attractive options to treat nasal breathing disorders. Most are limited to unwieldy devices to aid breathing or surgical alteration of the nasal anatomy. Startup Aerin Medical hopes to offer a novel noninvasive approach--the use of nonablative radiofrequency energy to target and remodel nasal tissues to treat breathing orders caused by anatomical obstruction and mucosal dysfunction.